Enrolled and Randomized<sup>a</sup>
N=260

**Motavizumab/Palivizumab**
- n=83
  - Discontinued, n (%) 6 (7.2)<sup>b</sup>
  - Withdrawal of consent 3 (3.6)
  - Death 2 (2.4)
  - Possibly related SAE after dose 1 1 (1.2)
  - Received 5 doses n=76 (91.6%)
    - Completed Study<sup>d</sup> n=77 (92.8%)

**Palivizumab/Motavizumab**
- n=84
  - Discontinued, n (%) 7 (8.3)
  - Withdrawal of consent 5 (6.0)
  - Lost to follow-up 1 (1.2)
  - Relocation 1 (1.2)
  - Received 5 doses n=79 (94.0%)
    - Completed Study<sup>d</sup> n=77 (91.7%)

**Motavizumab**
- n=93
  - Discontinued, n (%) 6 (6.5)<sup>c</sup>
    - Withdrawal of consent 6 (6.5)
  - Relocation 1 (1.2)
  - Lost to follow-up 1 (1.2)
  - Received 5 doses n=91 (97.8%)
    - Completed Study<sup>d</sup> n=87 (93.5%)